Revlis Biotech Company Limited.
Revlis Biotech Company Limited.
80,000,000+
ECG accumulated seconds measured
4,000,000+
Cumulative number of symptoms monitored by ECG |
3,000,000+
Cumulative ECG Measured
Leader in ECG Big Data and AI Technology
Since its establishment in 2003, Revlis Biotech Co., Ltd. has been committed to the development of digital health management. Through unique sensors and big data databases, it can measure a variety of physiological indexes originating from ECG, such as blood glucose, glycosylated hemoglobin, blood pressure, heart rate, etc. Among them, non-invasive blood glucose measurement is Revlis’ innovative and leading technology.
Cmate® End-to-End Solution
We provide an overall solution that includes smart terminal device/modules, SaaS service model and AI calculation engine. Its advantage lies in the modular architecture of software / hardware design, which can give partners more diversified and flexible applications, reduce entry barriers, and provide customized integrated development and sales services.
Globally Leading Cmate Multi-Dimensional AI Algorithm
We provide various health status indicators based on data and AI analysis, which can effectively help users improve the effectiveness of health management, and provide sustainable, high-accuracy, and low-burden premium health management solutions. |
The high-precision physiological indicators
The major physiological indicators can be monitored:
Create an affordable health to the world
As a provider of artificial intelligence technology, Revlis continues to develop more diversified physiological parameters and application levels in the field of ECG, and cooperates with technology industries and medical institutions in various fields to provide professional technical support, customized software development and big data operation and maintenance services, and provide innovative and affordable solutions to manage and track personal health and help people enjoy a healthy life.